PDF(Pubmed)
Abstract：
UNASSIGNED: Glomus tumors are typically benign soft tissue tumors that occur at the extremities; malignant and viscerally occurring cases are extremely rare.
UNASSIGNED: We report a 49-year old male patient with a malignant esophageal glomus tumor that was complicated by lung and liver metastases. Genetic test results guided the patient\'s individualized treatment. Consequently, treatment with Anlotinib combined with Tislelizumab achieved significant clinical benefits.
UNASSIGNED: Our case report demonstrates that immunotherapy combined with anti-angiogenic therapy in patients with malignant esophageal glomus tumors can achieve significant efficacy and suggests the potential value of next-generation sequencing (NGS) detection in guiding personalized treatments in patients with malignant esophageal glomus tumors.
UNASSIGNED: We report a 49-year old male patient with a malignant esophageal glomus tumor that was complicated by lung and liver metastases. Genetic test results guided the patient\'s individualized treatment. Consequently, treatment with Anlotinib combined with Tislelizumab achieved significant clinical benefits.
UNASSIGNED: Our case report demonstrates that immunotherapy combined with anti-angiogenic therapy in patients with malignant esophageal glomus tumors can achieve significant efficacy and suggests the potential value of next-generation sequencing (NGS) detection in guiding personalized treatments in patients with malignant esophageal glomus tumors.
摘要：
■血管球瘤是典型的良性软组织肿瘤，发生在四肢；恶性和内脏发生的病例极为罕见。
■我们报告了一名49岁的男性患者，患有恶性食管血管球瘤，并发肺和肝转移。基因检测结果指导患者的个体化治疗。因此,安洛替尼联合Tislelizumab治疗取得了显著的临床获益.
■我们的病例报告表明，在恶性食管血管球瘤患者中，免疫治疗联合抗血管生成治疗可以取得显著疗效，并提示下一代测序（NGS）检测在指导恶性食管血管球瘤患者个性化治疗方面的潜在价值。
■我们报告了一名49岁的男性患者，患有恶性食管血管球瘤，并发肺和肝转移。基因检测结果指导患者的个体化治疗。因此,安洛替尼联合Tislelizumab治疗取得了显著的临床获益.
■我们的病例报告表明，在恶性食管血管球瘤患者中，免疫治疗联合抗血管生成治疗可以取得显著疗效，并提示下一代测序（NGS）检测在指导恶性食管血管球瘤患者个性化治疗方面的潜在价值。
